GMED:NYSEGlobus Medical, Inc. Analysis
Data as of 2026-09-15 - not real-time
$74.33
Latest Price
4/10Risk
Risk Level: Medium
Executive Summary
Globus Medical, Inc. is priced at $74.33, and its moving averages give no clean directional read — the structure is neutral. It has lost 8.8% over the past 30 days. With RSI at 34.6 the momentum picture is approaching oversold, alongside a bearish MACD signal. Recent trading has carved out support near $72.84 and resistance around $88.89.
Multiples put this in undervalued territory: 19.0 times earnings against the sector's 29.9. Analyst price targets sit 38.9% above the current price. Revenue is growing at 5.9% on a 17.0% profit margin.
Risk scores 4 out of 10, which is moderate for this asset class. With 30-day volatility of 29.6%, a beta of 0.78 and a maximum drawdown of 24.0%, position sizing matters here. The wider market backdrop reads extreme greed at 90 on the fear-greed composite.
Near-term and long-term part ways here — hold short-term against buy longer out, with 6/10 conviction on the long call.
Multiples put this in undervalued territory: 19.0 times earnings against the sector's 29.9. Analyst price targets sit 38.9% above the current price. Revenue is growing at 5.9% on a 17.0% profit margin.
Risk scores 4 out of 10, which is moderate for this asset class. With 30-day volatility of 29.6%, a beta of 0.78 and a maximum drawdown of 24.0%, position sizing matters here. The wider market backdrop reads extreme greed at 90 on the fear-greed composite.
Near-term and long-term part ways here — hold short-term against buy longer out, with 6/10 conviction on the long call.
Top Market Events
Globus Medical NYSE:GMED announced that its Excelsius3D imaging system has received CE marking for use in the European...Medical device company Globus Medical NYSE:GMED announced in Q2 CY2026, with sales up 5.Globus Medical Inc GMED delivers record Q2 EPS with 56% growth, while navigating Nevro stabilization and enabling tech...
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 2/10
Key Factors
- Trading below the 200-day average of 85.56
- MACD momentum is negative
- 30-day price change of -8.8%
Medium Term
1–3 yearsPositive
Model confidence: 4/10
Key Factors
- P/E of 19.0 versus sector average of 29.9
- Trading below the 200-day average of 85.56
- Analyst targets imply +38.9% versus the current price
Long Term
> 3 yearsPositive
Model confidence: 6/10
Key Factors
- P/E of 19.0 versus sector average of 29.9
- Analyst targets imply +38.9% versus the current price
- Profit margin of 17.0% is healthy
Key Metrics & Analysis
Financial Health
Revenue Growth5.90%
Profit Margin17.03%
P/E Ratio19.0
ROE11.81%
ROA8.74%
Debt/Equity2.35
P/B Ratio2.1
Op. Cash Flow$910.4M
Free Cash Flow$554.2M
Industry P/E29.9
Technical Analysis
TrendNeutral
RSI34.6
Support$72.84
Resistance$88.89
MA 20$80.47
MA 50$80.22
MA 200$85.56
MACDBearish
VolumeIncreasing
Fear & Greed Index90.07
Valuation
Fair Value$69.05
Target Price$103.23
Upside/Downside38.89%
GradeUndervalued
TypeBlend
Risk Assessment
Beta0.78
Volatility29.62%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.